GlassScriptPhysician profile
Michael Maxino Soberano
NPI 1477596377
$2,733.53
in general payments reported to CMS, 2019-2025
23 companies · $394 in 2025
The $394 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $315 · 2021: $624 · 2022: $307 · 2023: $136 · 2024: $578 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $426.02 | 2020-2024 | Jornay Pm |
| Corium, LLC | $365.57 | 2021-2025 | Azstarys |
| Neos Therapeutics, LP | $311.42 | 2019-2024 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $271.93 | 2025 | Jornay Pm |
| Tris Pharma INC | $255.61 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $249.44 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $139.91 | 2019-2025 | Gardasil 9, Enflonsia, Proquad |
| Takeda Pharmaceuticals U.S.A., INC. | $127.57 | 2020-2022 | |
| Kaleo, INC. | $93.83 | 2021-2022 | |
| Adlon Therapeutics L.P. | $72.96 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $69.08 | 2023-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $52.41 | 2020-2021 | |
| Cranial Technologies, INC | $48.13 | 2021-2024 | Doc Band |
| Rhodes Pharmaceuticals L.P. | $40.81 | 2019 | |
| Phadia US INC. | $34.66 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $33.62 | 2025 | Relexxii |
| Alexion Pharmaceuticals, INC. | $31.25 | 2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $23.18 | 2019 | |
| Shire North American Group INC | $20.29 | 2019 | |
| Soleno Therapeutics, INC. | $20.04 | 2025 | Vykat Xr |
| Pfizer INC. | $16.71 | 2021 | |
| Alk-Abello, INC | $14.83 | 2025 | Neffy, Grastek, Odactra |
| Aytu Biopharma, INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Soberano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.